InterCure (NASDAQ:INCR) Stock Price Up 1.5% – What’s Next?

InterCure Ltd. (NASDAQ:INCR)’s share price rose 1.5% on Monday . The company traded as high as $0.9999 and last traded at $0.9760. 8,424 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 19,470 shares. The stock had previously closed at $0.9618.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, InterCure presently has an average rating of “Sell”.

InterCure Stock Up 1.5%

The company has a debt-to-equity ratio of 0.20, a current ratio of 1.48 and a quick ratio of 0.97. The firm has a market capitalization of $53.37 million, a P/E ratio of 32.53 and a beta of 1.40. The business has a 50 day moving average price of $0.98 and a 200 day moving average price of $0.89.

InterCure (NASDAQ:INCR) last announced its earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $23.15 million during the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.